The adult-specific 21-valent pneumococcal conjugate vaccine (V116) is well tolerated, and all 21 serotypes are immunogenic among patients with HIV infection. These findings were published in The Lancet HIV.
Compared with patients without HIV,…
V116 provides safe, effective, broader pneumococcal protection in patients with HIV
